Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent

Abstract

A RPS-specific postoperative nomogram was developed. It improves RPS staging by allowing a more dynamic and robust disease-specific risk stratification. This prognostic tool can help in patient counseling and for selection of high-risk patients that may benefit from adjuvant therapies or inclusion into clinical trials.

The Benefit of Adjuvant Radiotherapy in High-grade Nonmetastatic Retroperitoneal Soft Tissue Sarcoma

“…Advanced age has repeatedly been associated with worse outcomes in patients with RPS in multiple retrospective analyses. 4,17,51 In addition, a recent multicenter retrospective analysis from France showed male sex was associated with both increased risk of local failure (HR = 1.5, P = 0.006) and decreased OS (HR = 1.7, P < 0.001) on multivariate analysis, although the reason for this survival difference based on sex remains unclear. 52 This study has limitations inherent to any study using the SEER database.…”

Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications

“…However, this tool included histological entities, such as malignant fibrous histiocytoma, that are no longer included in World Health Organization sarcoma classification and all tumour sites. Since then, several nomograms have been developed, including histology-specific nomograms for liposarcomas 29 and synovial sarcomas, 30 site-specific nomograms for both extremity 31,32 and retroperitoneal sarcomas, 22,33,34 and also uterine leiomyosarcomas. 35 Among these nomograms, the 'Sarculator' (http://www.sarculator.com/) is a freely available online resource with embedded nomograms for retroperitoneal 22,36 and extremity 32 sarcomas.…”

Histologic Type Predicts Survival in Patients with Retroperitoneal Soft Tissue Sarcoma

“…Their tendency for locally advanced disease at presentation, difficulty to resect with widely clear margins, and predilection for local recurrences contribute to the complexity of their clinical management. Single-institution series have demonstrated 5-y overall survival rates ranging from 36% to 57% [1][2][3][4][5]. However, few patients are ultimately cured, and unlike many other malignancies, cancer-specific death for RPSTS is often the result of uncontrolled local disease rather than distant metastases [6].…”